# Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

> **NCT01535989** · PHASE1 · COMPLETED · sponsor: **Cristiana Sessa** · enrollment: 25 (actual)

## Conditions studied

- B-cell Lymphoma Refractory

## Interventions

- **DRUG:** Inotuzumab Ozogamicin
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01535989
- **Lead sponsor:** Cristiana Sessa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535989, "Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01535989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*